Researchers used CRISPR to remove the CD33 protein from donor stem cells, protecting healthy blood cells from therapies that ...

For highly aggressive types of blood cancer, stem cell transplantation is often the only potentially curative therapy. Yet, these cancers can often return even after a transplant. Notably, CAR T cell ...

For highly aggressive types of blood cancer, stem cell transplantation is often the only potentially curative therapy, yet even after a transplant, these cancers often return. Now a clinical trial, ...

Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across Germany, show that the genetic risk of disease, not remission status, ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. One important aspect of improving survival ...

Allo-HCT outcomes for TP53-mutated AML are similar across haploidentical, matched sibling, and matched unrelated donors. The study analyzed 451 patients, showing comparable 2-year overall survival and ...

Disparities in allo-HCT access for AML persist, particularly among non-Hispanic Black patients and those with lower socioeconomic status, despite increased donor availability. Financial burdens and ...

Nichola Smith, 44, was first diagnosed with acute myeloid leukaemia (AML) at the age of 12, beginning a decades-long battle ...

Dr. Gwen Nichols explains how Orca‑T may reduce graft-versus-host disease and impact treatment decisions for certain patients with blood cancers. As treatment options for acute myeloid leukemia (AML) ...